Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03118843) enrolled 31 participants, all of whom received a combination treatment referred to as SOF/VEL/VOX (a single group with no comparison group). All 31 participants completed the trial — none dropped out. The trial was primarily measuring two things: whether participants' hepatitis C virus (HCV) levels fell below a detectable threshold 12 weeks after finishing treatment (known as SVR12, a standard way of checking whether the virus is still detectable in the blood), and whether anyone had to permanently stop taking the study medication due to a bad reaction. The reported data shows that 100% of participants (all 31 people) had HCV levels below the detectable limit at both 4 weeks and 12 weeks after finishing treatment. The reported data also shows that 0% of participants permanently stopped the study medication due to an adverse event (an unwanted reaction). For the secondary measurements, the reported data shows that 0% of participants experienced what the trial defined as "virologic failure" — meaning the virus did not rebound or persist during treatment in any participant. During treatment itself, the proportion of participants with virus levels below the detectable limit rose over time, with figures reported at 51.6%, 96.8%, and 100% at successive measurement points. The reported data also includes measurements of how much HCV levels changed from the starting point during treatment, expressed as a log10 reduction (a technical way of describing a large drop in virus levels) — with reductions of around 5.16 to 5.34 log10 IU/mL reported across the on-treatment time points. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Hepatitis C Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- You are male, or female and not pregnant or breastfeeding, and are 18 years of age or older
- You have a long-term (chronic) Hepatitis C (HCV) infection
- You previously took part in a Hepatitis C treatment study sponsored by Gilead, but the treatment did not fully clear the virus from your body
Who may not be able to join:
- There may be additional requirements or restrictions not listed here (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gilead Study Director, Gilead Sciences
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12); Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.